Padakonn Pharma has been selected to join Health Founders Estonia (HFE) for the second consecutive year. As part of Batch II, the company will take part in the DEVELOP programme and work with the HFE team on the next stage of its growth.
Over the past year, Padakonn Pharma has expanded its technology from a single therapeutic approach for chronic kidney disease (CKD) into a broader monoclonal antibody platform for acute and chronic vascular diseases. The company has also launched its preclinical programme with support from EIS | Enterprise Estonia, strengthened international collaborations, joined the UK Government’s Global Entrepreneur Programme, and further sharpened its strategy.
Health Founders Estonia is the official government-backed operator of Estonia’s healthtech ecosystem. It brings together startups, healthcare providers, patient organisations, universities, policymakers, and investors to build a dynamic early-stage life science and digital health ecosystem. The DEVELOP programme gives Padakonn Pharma an opportunity to refine priorities, deepen partnerships, and prepare its platform for the next phase.
Congratulations to everyone selected for Batch II. Padakonn Pharma is excited to build alongside the other teams and thanks the entire Health Founders Estonia team for continuing to strengthen Estonia’s healthtech ecosystem.
